Mereo BioPharma Group (NASDAQ:MREO) Upgraded at Lifesci Capital

Lifesci Capital upgraded shares of Mereo BioPharma Group (NASDAQ:MREO) to a hold rating in a research report released on Thursday,Zacks.com reports.

Other equities analysts have also issued research reports about the company. Needham & Company LLC lowered their price objective on Mereo BioPharma Group from $5.00 to $3.00 and set a “buy” rating on the stock in a research note on Tuesday, January 13th. Jefferies Financial Group downgraded Mereo BioPharma Group from a “buy” rating to a “hold” rating in a research note on Tuesday, December 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Mereo BioPharma Group in a report on Thursday, January 22nd. Wall Street Zen lowered shares of Mereo BioPharma Group from a “hold” rating to a “sell” rating in a report on Saturday, January 3rd. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Mereo BioPharma Group in a research report on Monday, December 29th. Four analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $3.25.

Mereo BioPharma Group Price Performance

MREO opened at $0.34 on Thursday. The firm has a market capitalization of $54.42 million, a price-to-earnings ratio of -5.70 and a beta of 0.34. The company’s 50 day simple moving average is $0.44 and its two-hundred day simple moving average is $1.31. Mereo BioPharma Group has a 1-year low of $0.20 and a 1-year high of $3.05.

Mereo BioPharma Group (NASDAQ:MREO) last posted its quarterly earnings results on Thursday, March 19th. The company reported ($0.01) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.01). On average, equities analysts anticipate that Mereo BioPharma Group will post -0.03 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. grew its stake in shares of Mereo BioPharma Group by 0.3% in the first quarter. Goldman Sachs Group Inc. now owns 2,125,920 shares of the company’s stock valued at $4,783,000 after buying an additional 6,068 shares in the last quarter. Woodline Partners LP raised its holdings in shares of Mereo BioPharma Group by 53.2% in the 1st quarter. Woodline Partners LP now owns 947,986 shares of the company’s stock valued at $2,133,000 after buying an additional 329,202 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Mereo BioPharma Group by 62.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,569,100 shares of the company’s stock worth $3,530,000 after acquiring an additional 604,200 shares in the last quarter. XTX Topco Ltd purchased a new position in Mereo BioPharma Group during the 2nd quarter valued at about $188,000. Finally, Paloma Partners Management Co purchased a new position in Mereo BioPharma Group during the 2nd quarter valued at about $804,000. 62.83% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Mereo BioPharma Group

Here are the key news stories impacting Mereo BioPharma Group this week:

• Positive Sentiment: Company updates: Mereo published full‑year 2025 results and corporate highlights and said additional data analyses from the Orbit and Cosmic Phase 3 studies of setrusumab (UX143) in osteogenesis imperfecta are ongoing — a potential long‑term value driver if analyses produce positive signals. Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights
• Negative Sentiment: Earnings miss: Mereo reported quarterly EPS of ($0.05), missing the consensus of ($0.01). The larger-than-expected loss likely pressured sentiment and raises near‑term funding and execution concerns for a small biotech with limited market cap. Quarterly Financial Results Press Release
• Negative Sentiment: Legal / litigation risk: Multiple plaintiff law firms have announced or publicized a securities class action covering ADS purchases from June 5, 2023 through Dec 26, 2025 and are soliciting lead plaintiffs (April 6, 2026 deadline). The proliferation of filings and solicitations (Rosen, Schall, Faruqi, Bronstein, Berger Montague, Pomerantz, DJS, etc.) increases uncertainty and could lead to costly litigation or settlements. Rosen Law Firm Notice Bronstein, Gewirtz & Grossman Notice Faruqi & Faruqi Notice

Mereo BioPharma Group Company Profile

Mereo BioPharma Group plc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for rare diseases, oncology and severe respiratory conditions. The company pursues an asset‐centric model, in which it in-licenses or acquires clinical-stage small molecules and monoclonal antibodies with established safety profiles. By concentrating resources on a select number of programs, Mereo aims to accelerate proof-of-concept studies and maximize the potential value of each therapeutic candidate.

Mereo’s pipeline includes investigational therapies for skeletal disorders, such as setrusumab (BPS-804) for osteogenesis imperfecta, and treatments for acute and chronic respiratory diseases.